HealthMore in Health→
Amneal’s $375 Million Biosimilar Deal Signals Another Push for Scale in Drug Manufacturing
Key Takeaways
- Amneal Pharmaceuticals is set to acquire a biosimilar maker for $375 million upfront.
- The deal was highlighted in a manufacturing-focused industry roundup.
- The move suggests continued strategic interest in biosimilars as a growth and scale category.
DE
DT Editorial Team··via endpoints.news